NeuroSense ALS Drug PrimeC Hits Primary Endpoint in Phase 2B Study, Showing Significant TDP-43 Reduction
NRSN sits 19% above its 52-week low of $0.63 on elevated volume (5.7× avg).
Summary
NeuroSense Therapeutics' lead ALS drug, PrimeC, achieved its primary endpoint in a Phase 2B study, demonstrating a statistically significant reduction of TDP-43, a key biomarker for the disease. The study also reported a favorable safety profile over 18 months. This critical positive development follows recent insider share purchases and multiple patent grants for PrimeC, providing strong validation for the company's core asset. For a micro-cap biotech, this de-risks the drug significantly and is a major step towards potential late-stage development.
At the time of this announcement, NRSN was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.5M. The 52-week trading range was $0.63 to $2.19. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.